Post-earnings recap
Reported
Wed, May 4, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that 10X Genomics Inc faced challenges reflected in their EPS miss. However, the stock rose by 3.61%, indicating that investors may be optimistic about the company's long-term potential despite the current hurdles. The lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | -2.15% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced in the current market but expressed commitment to their strategic objectives. They did not provide specific guidance for future quarters.
Management highlighted ongoing challenges in the market environment.
They emphasized a focus on long-term growth despite short-term setbacks.